{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:48:54Z","timestamp":1792252134427,"version":"4.4.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"vor","delay-in-days":282,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101480","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:21:12Z","timestamp":1792214472000},"page":"101480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Concordance between tumor proportion score (TPS) and combined positive score (CPS) for PD-L1 expression in esophageal squamous cell carcinoma: a structured narrative review"],"prefix":"10.1016","volume":"49","author":[{"given":"Raquel P.","family":"Saraiva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6141-9796","authenticated-orcid":false,"given":"Tamara J.","family":"Huizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas P.L.","family":"Wijnhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjoerd M.","family":"Lagarde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Oudijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Mostert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ctarc.2026.101480_bib0001","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1007\/s12328-020-01237-x","article-title":"Epidemiology of esophageal cancer: update in global trends, etiology and risk factors","volume":"13","author":"Uhlenhopp","year":"2020","journal-title":"Clin. J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101480_bib0002","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101480_bib0003","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ctarc.2026.101480_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108790","article-title":"Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: a systematic review and network meta-analysis","volume":"109","author":"Li","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ctarc.2026.101480_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1009254","article-title":"Efficacy of PD-1\/PD-L1 inhibitors in patients with advanced gastroesophageal cancer: an updated meta-analysis based on randomized controlled trials","volume":"13","author":"Gu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ctarc.2026.101480_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1447021","article-title":"Toxicity in the era of immune checkpoint inhibitor therapy","volume":"15","author":"Keam","year":"2024","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101480_bib0007","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMa Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101480_bib0008","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-23319-1","article-title":"A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours","volume":"12","author":"Kang","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ctarc.2026.101480_bib0009","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fonc.2015.00073","article-title":"Epstein-barr virus in gastro-esophageal adenocarcinomas - single center experiences in the context of current literature","volume":"5","author":"Genitsch","year":"2015","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101480_bib0010","doi-asserted-by":"crossref","first-page":"330","DOI":"10.5858\/arpa.2018-0043-OA","article-title":"Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer","volume":"143","author":"Kulangara","year":"2019","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101480_bib0011","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41379-020-00710-9","article-title":"Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer","volume":"34","author":"Emancipator","year":"2021","journal-title":"Mod. Pathol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101480_bib0012","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10120-019-00999-9","article-title":"Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer","volume":"23","author":"Yamashita","year":"2020","journal-title":"Gastric. Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101480_bib0013","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13000-018-0689-9","article-title":"PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics","volume":"13","author":"Udall","year":"2018","journal-title":"Diagn. Pathol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101480_bib0014","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/his.14775","article-title":"High interobserver and intraobserver reproducibility among pathologists assessing PD-L1 CPS across multiple indications","volume":"81","author":"Nuti","year":"2022","journal-title":"Histopathology"},{"issue":"10294","key":"10.1016\/j.ctarc.2026.101480_bib0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101480_bib0016","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2217\/fon-2018-0609","article-title":"KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer","volume":"15","author":"Kato","year":"2019","journal-title":"Future Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101480_bib0017","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101480_bib0018","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","article-title":"Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Obermannova","year":"2022","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101480_bib0019","article-title":"A phase 2 trial combining pembrolizumab and palliative radiation therapy in gastroesophageal cancer to augment abscopal immune responses","volume":"7","author":"Chao","year":"2022","journal-title":"Adv. Radiat. Oncol."},{"key":"10.1016\/j.ctarc.2026.101480_bib0020","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s10388-022-00978-7","article-title":"The impact of combined PD-L1 positive score on clinical response to nivolumab in patients with advanced esophageal squamous cell carcinoma","volume":"20","author":"Matsubara","year":"2023","journal-title":"Esophagus"},{"key":"10.1016\/j.ctarc.2026.101480_bib0023","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-068714","article-title":"Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (orient-15): multicentre, randomised, double blind, phase 3 trial","volume":"377","author":"Lu","year":"2022","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101480_bib0025","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41467-022-28408-3","article-title":"Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (orient-2)","volume":"13","author":"Xu","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ctarc.2026.101480_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2022.106680","article-title":"Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: a prospective, single-arm, phase II study (td-NICE)","volume":"103","author":"Yan","year":"2022","journal-title":"Int. J. Surg."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101480_bib0021","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4143\/crt.2020.1198","article-title":"Real-world efficacy data and predictive clinical parameters for treatment outcomes in advanced esophageal squamous cell carcinoma treated with immune checkpoint inhibitors","volume":"54","author":"Kim","year":"2022","journal-title":"Cancer Res. Treat."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101480_bib0022","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00262-020-02766-7","article-title":"Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect","volume":"70","author":"Lee","year":"2021","journal-title":"Cancer Immunol. Immunther."},{"key":"10.1016\/j.ctarc.2026.101480_bib0024","article-title":"Expression and correlation of PD-L1 and HER2 in oesophageal squamous cell carcinoma","author":"Rong","year":"2023","journal-title":"J. Clin. Pathol."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101480_bib0027","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3390\/jpm12071073","article-title":"Atlas of PD-L1 for pathologists: indications, scores, diagnostic platforms and reporting systems","volume":"12","author":"Marletta","year":"2022","journal-title":"J. Pers. Med."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101480_bib0028","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41422-020-0337-2","article-title":"The future of cancer immunotherapy: microenvironment-targeting combinations","volume":"30","author":"Murciano-Goroff","year":"2020","journal-title":"Cell Res."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101480_bib0029","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy","volume":"124","author":"Raskov","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"16","key":"10.1016\/j.ctarc.2026.101480_bib0030","doi-asserted-by":"crossref","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr. Biol."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101480_bib0031","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1001\/jamaoncol.2022.3707","article-title":"Association of PD-L1 expression and other variables with benefit from immune checkpoint inhibition in advanced gastroesophageal cancer: Systematic review and meta-analysis of 17 phase 3 randomized clinical trials","volume":"8","author":"Yoon","year":"2022","journal-title":"JAMa Oncol."},{"key":"10.1016\/j.ctarc.2026.101480_bib0032","article-title":"From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1\/PD-L1 blockades","volume":"13","author":"Zhao","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ctarc.2026.101480_bib0033","article-title":"High interobserver variability among pathologists using combined positive score to evaluate PD-L1 expression in gastric, gastroesophageal junction and esophageal adenocarcinoma","volume":"36","author":"Robert","year":"2023","journal-title":"Mod. Pathol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101480_bib0034","doi-asserted-by":"crossref","first-page":"661","DOI":"10.4143\/crt.2019.718","article-title":"PD-L1 testing in gastric cancer by the combined positive score of the 22C3 PharmDx and SP263 assay with clinically relevant cut-offs","volume":"52","author":"Park","year":"2020","journal-title":"Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101480_bib0035","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 ihc assay comparison project","volume":"12","author":"Hirsch","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ctarc.2026.101480_bib0036","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1200\/PO.20.00412","article-title":"Analytical concordance of PD-L1 assays utilizing antibodies from FDA-approved diagnostics in advanced cancers: a systematic literature review","volume":"5","author":"Prince","year":"2021","journal-title":"JCo Precis. Oncol."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101480_bib0037","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/s41379-019-0210-3","article-title":"Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases","volume":"32","author":"O'Malley","year":"2019","journal-title":"Mod. Pathol."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101480_bib0038","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jtho.2018.05.013","article-title":"PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project","volume":"13","author":"Tsao","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101480_bib0039","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.21037\/jgo-21-505","article-title":"PD-L1 immunohistochemistry comparison of 22C3 and 28-8 assays for gastric cancer","volume":"12","author":"Narita","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101480_bib0040","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/s41379-020-0644-7","article-title":"Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC)","volume":"34","author":"de Ruiter","year":"2021","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ctarc.2026.101480_bib0041","article-title":"Eortc stomach cancer PD-L1 biomarker european initiative: the aspire study protocol","volume":"5","author":"Petrillo","year":"2024","journal-title":"ESMO Gastrointestinal Oncol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003898?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003898?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:15:28Z","timestamp":1792250128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226003898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":41,"alternative-id":["S2468294226003898"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101480","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concordance between tumor proportion score (TPS) and combined positive score (CPS) for PD-L1 expression in esophageal squamous cell carcinoma: a structured narrative review","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101480","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101480"}}